ID   KALRN_HUMAN             Reviewed;        2985 AA.
AC   O60229; A8MSI4; Q6ZN45; Q8TBQ5; Q9NSZ4; Q9Y2A5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-2007, sequence version 2.
DT   02-NOV-2010, entry version 107.
DE   RecName: Full=Kalirin;
DE            EC=2.7.11.1;
DE   AltName: Full=Huntingtin-associated protein-interacting protein;
DE   AltName: Full=Protein Duo;
DE   AltName: Full=Serine/threonine-protein kinase with Dbl- and pleckstrin homology domain;
GN   Name=KALRN; Synonyms=DUET, DUO, HAPIP, TRAD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Frontal cortex;
RX   MEDLINE=97449175; PubMed=9285789; DOI=10.1093/hmg/6.9.1519;
RA   Colomer V., Engelender S., Sharp A.H., Duan K., Cooper J.K.,
RA   Lanahan A., Lyford G., Worley P., Ross C.A.;
RT   "Huntingtin-associated protein 1 (HAP1) binds to a Trio-like
RT   polypeptide, with a rac1 guanine nucleotide exchange factor domain.";
RL   Hum. Mol. Genet. 6:1519-1525(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, MUTAGENESIS OF
RP   LYS-2712, AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=99148017; PubMed=10023074; DOI=10.1016/S0378-1119(98)00605-2;
RA   Kawai T., Sanjo H., Akira S.;
RT   "Duet is a novel serine/threonine kinase with Dbl-homology (DH) and
RT   pleckstrin-homology (PH) domains.";
RL   Gene 227:249-255(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5).
RC   TISSUE=Amygdala, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1917 (ISOFORM 3), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2104-2985 (ISOFORM 5).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2016-2985 (ISOFORM 5).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1773, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   INVOLVEMENT IN CHDS5.
RX   PubMed=17357071; DOI=10.1086/512981;
RA   Wang L., Hauser E.R., Shah S.H., Pericak-Vance M.A., Haynes C.,
RA   Crosslin D., Harris M. II, Nelson S., Hale A.B., Granger C.B.,
RA   Haines J.L., Jones C.J.H., Crossman D., Seo D., Gregory S.G.,
RA   Kraus W.E., Goldschmidt-Clermont P.J., Vance J.M.;
RT   "Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a
RT   novel candidate gene for coronary artery disease.";
RL   Am. J. Hum. Genet. 80:650-663(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1750; SER-1753;
RP   SER-1756; SER-1799; SER-1817 AND SER-2261, AND MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1799 AND SER-2236, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-213 AND CYS-1896.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [12]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-196.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Promotes the exchange of GDP by GTP. Activates specific
CC       Rho GTPase family members, thereby inducing various signaling
CC       mechanisms that regulate neuronal shape, growth, and plasticity,
CC       through their effects on the actin cytoskeleton. Induces
CC       lamellipodia independent of its GEF activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- SUBUNIT: Interacts with the C-terminal of peptidylglycine alpha-
CC       amidating monooxygenase (PAM) and with the huntingtin-associated
CC       protein 1 (HAP1) (By similarity).
CC   -!- INTERACTION:
CC       P48023:FASLG; NbExp=1; IntAct=EBI-949233, EBI-495538;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton.
CC       Note=Associated with the cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=6;
CC       Name=1;
CC         IsoId=O60229-1; Sequence=Displayed;
CC         Note=Produced by alternative splicing;
CC       Name=2;
CC         IsoId=O60229-2; Sequence=VSP_028910, VSP_028911;
CC         Note=Produced by alternative splicing. No experimental
CC         confirmation available;
CC       Name=3;
CC         IsoId=O60229-3; Sequence=VSP_028905, VSP_028906, VSP_028907,
CC                                  VSP_028908;
CC         Note=Produced by alternative initiation at Met-624 of isoform 1.
CC         Inferred by similarity;
CC       Name=4; Synonyms=DUET, TRAD;
CC         IsoId=O60229-4; Sequence=VSP_028903, VSP_028912;
CC         Note=Produced by alternative splicing;
CC       Name=5;
CC         IsoId=O60229-5; Sequence=VSP_028904, VSP_028909, VSP_028913,
CC                                  VSP_028914, VSP_028915;
CC         Note=Produced by alternative splicing;
CC       Name=6;
CC         IsoId=O60229-6; Sequence=VSP_028903, VSP_028912, VSP_028913;
CC         Note=Produced by alternative splicing. No experimental
CC         confirmation available;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is brain specific. Highly expressed
CC       in cerebral cortex, putamen, amygdala, hippocampus and caudate
CC       nucleus. Weakly expressed in brain stem and cerebellum. Isoform 4
CC       is expressed in skeletal muscle.
CC   -!- DOMAIN: The two GEF domains catalyze nucleotide exchange for RAC1
CC       and RhoA which are bound by DH1 and DH2 respectively. The two GEF
CC       domains appear to play differing roles in neuronal development and
CC       axonal outgrowth. SH3 1 binds to the first GEF domain inhibiting
CC       GEF activity only when in the presence of a PXXP peptide,
CC       suggesting that the SH3 domain/peptide interaction mediates
CC       binding to GEF1. CRK1 SH3 domain binds to and inhibits GEF1
CC       activity (By similarity).
CC   -!- PTM: Autophosphorylated.
CC   -!- DISEASE: Genetic variation in KALRN is associated with
CC       susceptibility to coronary heart disease type 5 (CHDS5)
CC       [MIM:608901]. CHD is the leading cause of death and disability
CC       worldwide. CHD is multifactorial disease with a strong genetic
CC       component. Classic epidemiologic studies have revealed many risk
CC       factors for CHD, including age, sex, hypertension, dyslipidemia,
CC       diabetes mellitus, smoking, and physical inactivity.
CC   -!- MISCELLANEOUS: Called DUO because the encoded protein is closely
CC       related to but shorter than TRIO.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family.
CC   -!- SIMILARITY: Contains 1 CRAL-TRIO domain.
CC   -!- SIMILARITY: Contains 2 DH (DBL-homology) domains.
CC   -!- SIMILARITY: Contains 1 fibronectin type-III domain.
CC   -!- SIMILARITY: Contains 1 Ig-like C2-type (immunoglobulin-like)
CC       domain.
CC   -!- SIMILARITY: Contains 2 PH domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 2 SH3 domains.
CC   -!- SIMILARITY: Contains 5 spectrin repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH58015.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U94190; AAC15791.1; -; mRNA.
DR   EMBL; AB011422; BAA76314.1; -; mRNA.
DR   EMBL; AK125979; BAC86373.1; -; mRNA.
DR   EMBL; AK131379; BAD18530.1; -; mRNA.
DR   EMBL; AC022336; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069233; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC080008; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112129; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC117401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC026865; AAH26865.1; -; mRNA.
DR   EMBL; BC058015; AAH58015.1; ALT_SEQ; mRNA.
DR   EMBL; AL137629; CAB70850.1; -; mRNA.
DR   IPI; IPI00021156; -.
DR   IPI; IPI00028382; -.
DR   IPI; IPI00410727; -.
DR   IPI; IPI00410728; -.
DR   IPI; IPI00607777; -.
DR   IPI; IPI00794432; -.
DR   PIR; T46482; T46482.
DR   RefSeq; NP_001019831.2; -.
DR   RefSeq; NP_003938.1; -.
DR   RefSeq; NP_008995.2; -.
DR   UniGene; Hs.8004; -.
DR   ProteinModelPortal; O60229; -.
DR   IntAct; O60229; 6.
DR   MINT; MINT-2865643; -.
DR   STRING; O60229; -.
DR   PhosphoSite; O60229; -.
DR   PRIDE; O60229; -.
DR   Ensembl; ENST00000360013; ENSP00000353109; ENSG00000160145.
DR   GeneID; 8997; -.
DR   KEGG; hsa:8997; -.
DR   UCSC; uc003ehf.1; human.
DR   UCSC; uc003ehi.2; human.
DR   UCSC; uc003ehk.1; human.
DR   CTD; 8997; -.
DR   GeneCards; GC03P123798; -.
DR   HGNC; HGNC:4814; KALRN.
DR   HPA; CAB026456; -.
DR   HPA; HPA011913; -.
DR   MIM; 604605; gene.
DR   MIM; 608901; phenotype.
DR   PharmGKB; PA29189; -.
DR   eggNOG; prNOG16621; -.
DR   HOGENOM; HBG714943; -.
DR   HOVERGEN; HBG108598; -.
DR   InParanoid; O60229; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; arf6downstreampathway; Arf6 downstream pathway.
DR   Pathway_Interaction_DB; ephbfwdpathway; EPHB forward signaling.
DR   Reactome; REACT_11044; Signaling by Rho GTPases.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   NextBio; 33739; -.
DR   ArrayExpress; O60229; -.
DR   Bgee; O60229; -.
DR   CleanEx; HS_KALRN; -.
DR   Genevestigator; O60229; -.
DR   GermOnline; ENSG00000160145; Homo sapiens.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0005089; F:Rho guanyl-nucleotide exchange factor activity; IEA:InterPro.
DR   GO; GO:0006915; P:apoptosis; EXP:Reactome.
DR   GO; GO:0008624; P:induction of apoptosis by extracellular sig...; EXP:Reactome.
DR   GO; GO:0023034; P:intracellular signaling pathway; ISS:HGNC.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016192; P:vesicle-mediated transport; TAS:ProtInc.
DR   InterPro; IPR001251; CRAL-bd_TRIO_C.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   Gene3D; G3DSA:3.40.525.10; CRAL_bd_TRIO_C; 1.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 2.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 2.
DR   Gene3D; G3DSA:1.20.900.10; RhoGEF; 2.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00621; RhoGEF; 2.
DR   Pfam; PF00435; Spectrin; 4.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00325; RhoGEF; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SMART; SM00326; SH3; 2.
DR   SMART; SM00150; SPEC; 7.
DR   SUPFAM; SSF52087; CRAL_TRIO_C; 1.
DR   SUPFAM; SSF48065; DH-domain; 2.
DR   SUPFAM; SSF49265; FN_III-like; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 2.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS00741; DH_1; FALSE_NEG.
DR   PROSITE; PS50010; DH_2; 2.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   Alternative initiation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disulfide bond;
KW   Guanine-nucleotide releasing factor; Immunoglobulin domain; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Repeat; Serine/threonine-protein kinase; SH3 domain;
KW   Transferase.
FT   CHAIN         1   2985       Kalirin.
FT                                /FTId=PRO_0000080955.
FT   DOMAIN       35    180       CRAL-TRIO.
FT   REPEAT      188    308       Spectrin 1.
FT   REPEAT      310    416       Spectrin 2.
FT   REPEAT      536    642       Spectrin 3.
FT   REPEAT      890   1004       Spectrin 4.
FT   REPEAT     1130   1222       Spectrin 5.
FT   DOMAIN     1281   1456       DH 1.
FT   DOMAIN     1468   1580       PH 1.
FT   DOMAIN     1646   1711       SH3 1.
FT   DOMAIN     1928   2103       DH 2.
FT   DOMAIN     2115   2225       PH 2.
FT   DOMAIN     2320   2385       SH3 2.
FT   DOMAIN     2470   2563       Ig-like C2-type.
FT   DOMAIN     2568   2659       Fibronectin type-III.
FT   DOMAIN     2683   2937       Protein kinase.
FT   NP_BIND    2689   2697       ATP (By similarity).
FT   COMPBIAS    682    687       Poly-Gln.
FT   ACT_SITE   2802   2802       Proton acceptor (By similarity).
FT   BINDING    2712   2712       ATP.
FT   MOD_RES    1750   1750       Phosphoserine.
FT   MOD_RES    1753   1753       Phosphoserine.
FT   MOD_RES    1756   1756       Phosphoserine.
FT   MOD_RES    1773   1773       Phosphoserine.
FT   MOD_RES    1799   1799       Phosphoserine.
FT   MOD_RES    1817   1817       Phosphoserine.
FT   MOD_RES    2236   2236       Phosphoserine.
FT   MOD_RES    2261   2261       Phosphoserine.
FT   DISULFID   2491   2547       By similarity.
FT   VAR_SEQ       1   1697       Missing (in isoform 4 and isoform 6).
FT                                /FTId=VSP_028903.
FT   VAR_SEQ       1   1627       Missing (in isoform 5).
FT                                /FTId=VSP_028904.
FT   VAR_SEQ       1    641       Missing (in isoform 3).
FT                                /FTId=VSP_028905.
FT   VAR_SEQ     709    721       Missing (in isoform 3).
FT                                /FTId=VSP_028906.
FT   VAR_SEQ    1465   1505       FDENLDVQGELILQDAFQVWDPKSLIRKGRERHLFLFEISL
FT                                -> SCPPSTGEASSLPRHGGACIMGGKWHEVRQGARLEERR
FT                                NDK (in isoform 3).
FT                                /FTId=VSP_028907.
FT   VAR_SEQ    1506   2985       Missing (in isoform 3).
FT                                /FTId=VSP_028908.
FT   VAR_SEQ    1628   1643       ISIASRTSQNTVDSDK -> MLKWISWRQSKANKAQ (in
FT                                isoform 5).
FT                                /FTId=VSP_028909.
FT   VAR_SEQ    1644   1663       LSGGCELTVVLQDFSAGHSS -> DGNLVPRWHLGPGDPFS
FT                                TYV (in isoform 2).
FT                                /FTId=VSP_028910.
FT   VAR_SEQ    1664   2985       Missing (in isoform 2).
FT                                /FTId=VSP_028911.
FT   VAR_SEQ    1698   1725       EGLVPSSALCISHSRSSVEMDCFFPLVK -> MKGGDRAYT
FT                                RGPSLGWLFAKCCCCFPCR (in isoform 4 and
FT                                isoform 6).
FT                                /FTId=VSP_028912.
FT   VAR_SEQ    1857   1887       Missing (in isoform 5 and isoform 6).
FT                                /FTId=VSP_028913.
FT   VAR_SEQ    2313   2313       Missing (in isoform 5).
FT                                /FTId=VSP_028914.
FT   VAR_SEQ    2398   2985       Missing (in isoform 5).
FT                                /FTId=VSP_028915.
FT   VARIANT     196    196       S -> L.
FT                                /FTId=VAR_041898.
FT   VARIANT     213    213       R -> W (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035976.
FT   VARIANT    1326   1326       E -> D (in dbSNP:rs2289838).
FT                                /FTId=VAR_020192.
FT   VARIANT    1896   1896       S -> C (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035625.
FT   VARIANT    1929   1929       R -> M (in dbSNP:rs35298864).
FT                                /FTId=VAR_057190.
FT   MUTAGEN    2712   2712       K->A: Loss of autophosphorylation.
FT   CONFLICT   1857   1857       S -> SS (in Ref. 2; BAA76314).
FT   CONFLICT   2458   2458       E -> G (in Ref. 2; BAA76314).
SQ   SEQUENCE   2985 AA;  340174 MW;  F4C01D0F2422A92F CRC64;
     MTDRFWDQWY LWYLRLLRLL DRGSFRNDGL KASDVLPILK EKVAFVSGGR DKRGGPILTF
     PARSNHDRIR QEDLRKLVTY LASVPSEDVC KRGFTVIIDM RGSKWDLIKP LLKTLQEAFP
     AEIHVALIIK PDNFWQKQKT NFGSSKFIFE TSMVSVEGLT KLVDPSQLTE EFDGSLDYNH
     EEWIELRLSL EEFFNSAVHL LSRLEDLQEM LARKEFPVDV EGSRRLIDEH TQLKKKVLKA
     PVEELDREGQ RLLQCIRCSD GFSGRNCIPG SADFQSLVPK ITSLLDKLHS TRQHLHQMWH
     VRKLKLDQCF QLRLFEQDAE KMFDWISHNK ELFLQSHTEI GVSYQYALDL QTQHNHFAMN
     SMNAYVNINR IMSVASRLSE AGHYASQQIK QISTQLDQEW KSFAAALDER STILAMSAVF
     HQKAEQFLSG VDAWCKMCSE GGLPSEMQDL ELAIHHHQTL YEQVTQAYTE VSQDGKALLD
     VLQRPLSPGN SESLTATANY SKAVHQVLDV VHEVLHHQRR LESIWQHRKV RLHQRLQLCV
     FQQDVQQVLD WIENHGEAFL SKHTGVGKSL HRARALQKRH DDFEEVAQNT YTNADKLLEA
     AEQLAQTGEC DPEEIYKAAR HLEVRIQDFV RRVEQRKLLL DMSVSFHTHT KELWTWMEDL
     QKEMLEDVCA DSVDAVQELI KQFQQQQTAT LDATLNVIKE GEDLIQQLRS APPSLGEPSE
     ARDSAVSNNK TPHSSSISHI ESVLQQLDDA QVQMEELFHE RKIKLDIFLQ LRIFEQYTIE
     VTAELDAWNE DLLRQMNDFN TEDLTLAEQR LQRHTERKLA MNNMTFEVIQ QGQDLHQYIT
     EVQASGIELI CEKDIDLAAQ VQELLEFLHE KQHELELNAE QTHKRLEQCL QLRHLQAEVK
     QVLGWIRNGE SMLNASLVNA SSLSEAEQLQ REHEQFQLAI ESLFHATSLQ KTHQSALQVQ
     QKAEVLLQAG HYDADAIREC AEKVALHWQQ LMLKMEDRLK LVNASVAFYK TSEQVCSVLE
     SLEQEYRRDE DWCGGRDKLG PAAEIDHVIP LISKHLEQKE AFLKACTLAR RNAEVFLKYI
     HRNNVSMPSV ASHTRGPEQQ VKAILSELLQ RENRVLHFWT LKKRRLDQCQ QYVVFERSAK
     QALDWIQETG EFYLSTHTST GETTEETQEL LKEYGEFRVP AKQTKEKVKL LIQLADSFVE
     KGHIHATEIR KWVTTVDKHY RDFSLRMGKY RYSLEKALGV NTEDNKDLEL DIIPASLSDR
     EVKLRDANHE VNEEKRKSAR KKEFIMAELL QTEKAYVRDL HECLETYLWE MTSGVEEIPP
     GILNKEHIIF GNIQEIYDFH NNIFLKELEK YEQLPEDVGH CFVTWADKFQ MYVTYCKNKP
     DSNQLILEHA GTFFDEIQQR HGLANSISSY LIKPVQRITK YQLLLKELLT CCEEGKGELK
     DGLEVMLSVP KKANDAMHVS MLEGFDENLD VQGELILQDA FQVWDPKSLI RKGRERHLFL
     FEISLVFSKE IKDSSGHTKY VYKNKLLTSE LGVTEHVEGD PCKFALWSGR TPSSDNKTVL
     KASNIETKQE WIKNIREVIQ ERIIHLKGAL KEPLQLPKTP AKQRNNSKRD GVEDIDSQGD
     GSSQPDTISI ASRTSQNTVD SDKLSGGCEL TVVLQDFSAG HSSELTIQVG QTVELLERPS
     ERPGWCLVRT TERSPPLEGL VPSSALCISH SRSSVEMDCF FPLVKDAYSH SSSENGGKSE
     SVANLQAQPS LNSIHSSPGP KRSTNTLKKW LTSPVRRLNS GKADGNIKKQ KKVRDGRKSF
     DLGSPKPGDE TTPQGDSADE KSKKGWGEDE PDEESHTPLP PPMKIFDNDP TQDEMSSLLA
     ARQASTEVPT AADLVNAIEK LVKNKLSLEG SSYRGSLKDP AGCLNEGMAP PTPPKNPEEE
     QKAKALRGRM FVLNELVQTE KDYVKDLGIV VEGFMKRIEE KGVPEDMRGK DKIVFGNIHQ
     IYDWHKDFFL AELEKCIQEQ DRLAQLFIKH ERKLHIYVWY CQNKPRSEYI VAEYDAYFEE
     VKQEINQRLT LSDFLIKPIQ RITKYQLLLK DFLRYSEKAG LECSDIEKAV ELMCLVPKRC
     NDMMNLGRLQ GFEGTLTAQG KLLQQDTFYV IELDAGMQSR TKERRVFLFE QIVIFSELLR
     KGSLTPGYMF KRSIKMNYLV LEENVDNDPC KFALMNRETS ERVVLQAANA DIQQAWVQDI
     NQVLETQRDF LNALQSPIEY QRKERSTAVM RSQPARLPQA SPRPYSSVPA GSEKPPKGSS
     YNPPLPPLKI STSNGSPGFE YHQPGDKFEA SKQNDLGGCN GTSSMAVIKD YYALKENEIC
     VSQGEVVQVL AVNQQNMCLV YQPASDHSPA AEGWVPGSIL APLTKATAAE SSDGSIKKSC
     SWHTLRMRKR AEVENTGKNE ATGPRKPKDI LGNKVSVKET NSSEESECDD LDPNTSMEIL
     NPNFIQEVAP EFLVPLVDVT CLLGDTVILQ CKVCGRPKPT ITWKGPDQNI LDTDNSSATY
     TVSSCDSGEI TLKICNLMPQ DSGIYTCIAT NDHGTTSTSA TVKVQGVPAA PNRPIAQERS
     CTSVILRWLP PSSTGNCTIS GYTVEYREEG SQIWQQSVAS TLDTYLVIED LSPGCPYQFR
     VSASNPWGIS LPSEPSEFVR LPEYDAAADG ATISWKENFD SAYTELNEIG RGRFSIVKKC
     IHKATRKDVA VKFVSKKMKK KEQAAHEAAL LQHLQHPQYI TLHDTYESPT SYILILELMD
     DGRLLDYLMN HDELMEEKVA FYIRDIMEAL QYLHNCRVAH LDIKPENLLI DLRIPVPRVK
     LIDLEDAVQI SGHFHIHHLL GNPEFAAPEV IQGIPVSLGT DIWSIGVLTY VMLSGVSPFL
     DESKEETCIN VCRVDFSFPH EYFCGVSNAA RDFINVILQE DFRRRPTAAT CLQHPWLQPH
     NGSYSKIPLD TSRLACFIER RKHQNDVRPI PNVKSYIVNR VNQGT
//
